Bristol-Myers Squibb Company ( (BMY) ) has released its Q2 earnings. Here is a breakdown of the information Bristol-Myers Squibb Company presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, primarily in the sectors of oncology, immunology, and cardiovascular diseases.
In its second quarter financial results for 2025, Bristol-Myers Squibb reported revenues of $12.3 billion, with a notable 18% increase in its Growth Portfolio, driven by strong performance in its immuno-oncology segment and strategic partnerships. The company also raised its 2025 revenue guidance, reflecting confidence in its long-term growth strategy.
Key financial highlights include a GAAP EPS of $0.64 and a non-GAAP EPS of $1.46, both impacted by a charge related to a strategic partnership with BioNTech. The Growth Portfolio’s revenue growth was primarily driven by products like Breyanzi, Reblozyl, and Camzyos, while the Legacy Portfolio saw a decline due to generic competition and Medicare Part D redesign impacts. The company also reported a decrease in gross margin and operating expenses, attributed to strategic productivity initiatives.
Looking ahead, Bristol-Myers Squibb remains focused on advancing its pipeline and growth portfolio, with expectations of continued revenue growth and strategic investments in innovative medicines. The company’s updated guidance reflects its commitment to delivering long-term value to shareholders and patients alike.